LBA55 - Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

S.T Tagawa,A Balar,D.P Petrylak,P Grivas,N Agarwal,C.N Sternberg,Q Hong,A Gladden,C Kanwal,P Siemon-Hryczyk,T Goswami,L.M Itri,Y Loriot

doi:10.1093/annonc/mdz394.049

LBA55 - Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

S.T Tagawa, A Balar + Show 11 more

Open Access

https://doi.org/10.1093/annonc/mdz394.049

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 23	License type: elsevier-specific: oa user license

Affiliation: New York University, University of Washington, Huntsman (United States), Immunomedics (United States), Institut Gustave Roussy

#Research Grant #Expert Testimony + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA55 - Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

Full Text